• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

iShares Neuroscience And Healthcare ETF(IBRN.US)

Last Updated 19:00:00 ET
longbridge loading
News
Holdings
Overview
Company Encyclopedia
View More
name
iShares Neuroscience And Healthcare ETF
IBRN.US
Shareholder
Ownership%OwnedShare ChgReport Date
No Data
News
View More

Sector Update: Health Care Stocks Rise in Afternoon Trading

Health care stocks experienced a rise in afternoon trading, with the NYSE Health Care Index up 1%. Dr. Reddy's Laboratories plans to sell a generic version of Novo Nordisk's Ozempic, leading to a 2.5% gain in its shares. Johnson & Johnson's full-year sales outlook exceeded expectations, despite a 0.8% drop in shares. Merck is collaborating on a $30 million program to update its Ebola vaccine, resulting in a 1.9% share increase. CVS Health faces a class action regarding higher fees for tobacco users, with shares up 2.1%.

fidelity·01/22/2026 02:40
fidelity·01/22/2026 02:40

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks experienced a slight decline, with the NYSE Health Care Index down 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3%. Capricor Therapeutics (CAPR) shares fell 2.3% following an FDA request for a full clinical study report. Qiagen (QGEN) shares surged 19% amid takeover interest, while Abivax (ABVX) shares rose 0.5% after its CEO dismissed takeover rumors from Eli Lilly (LLY), which saw a 0.2% increase.

fidelity·01/21/2026 03:04
fidelity·01/21/2026 03:04
© 2026 Longbridge|Disclaimer

Schedules & Filings

Schedules
Filings
Dec19
Distribution Plan(EST)

Cash dividend 0.3198 USD

Dec16
Distribution Plan(EST)

Cash dividend 0.3198 USD

Distribution Plan(EST)

Cash dividend 0.3198 USD

View More

Event Tracking

Jan21
Massachusetts Financial Services Increased Holdings in Biogen Inc.
11:19
Jan20
Axsome Therapeutics Price Target Raised to $260
17:42
Jan15
Mizuho Maintains Buy Rating on Axsome Therapeutics
17:21
Axsome Therapeutics Initiates AXS-14 Phase 3 Clinical Trial
12:00
Goldman Sachs Gives Biogen a 'Buy' Rating with a Target Price of $225
09:12
Jan14
Jefferies analyst reiterates buy rating on Biogen
14:17